Overall a very positive article with some insight into the strategic vision of the company.
“ Recce has its eyes on the Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) global initiative, which is offering a $1 billion reward for each new antibiotic approved, as well as increased R&D funding.“
However also looks as if a CR might be coming our way.
“January 2016. It raised A$5 million in its IPO, and the funds raised helped the complete preclinical trials and establish a manufacturing facility to prepare for phase I trials. Graham said the company has completed those goals and will raise money to conduct phase I trials. “
Ann: RECCE Antibiotic International Media Attention, page-2
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
39.0¢ |
Change
-0.030(7.14%) |
Mkt cap ! $115.6M | |||
| Open | High | Low | Value | Volume |
| 40.0¢ | 42.0¢ | 39.0¢ | $65.95K | 162.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 12 | 38.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 39.5¢ | 1580 | 2 |
View Market Depth
| Last trade - 15.07pm 29/07/2025 (20 minute delay) ? |
| RCE (ASX) Chart |